Jim Simons Aclaris Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 922,200 shares of ACRS stock, worth $1.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

922,200

Previous 1,673,400 44.89%

Holding current value

$1.93 Million

Previous $2.08 Million 51.13%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$1.01 - $1.36 $758,712 - $1.02 Million	-751,200 Reduced 44.89%	922,200 $1.01 Million
Q1 2024 May 13, 2024	SELL	$0.92 - $1.44 $67,189 - $105,166	-73,032 Reduced 4.18%	1,673,400 $2.08 Million
Q4 2023 Feb 13, 2024	BUY	$0.64 - $6.49 $703,219 - $7.13 Million	1,098,780 Added 169.66%	1,746,432 $1.83 Million
Q3 2023 Nov 14, 2023	SELL	$6.56 - $10.95 $2.11 Million - $3.52 Million	-321,900 Reduced 33.2%	647,652 $4.44 Million
Q2 2023 Aug 11, 2023	SELL	$7.89 - $10.64 $2.23 Million - $3.01 Million	-282,600 Reduced 22.57%	969,552 $10.1 Million
Q1 2023 May 12, 2023	BUY	$7.07 - $17.95 $921,928 - $2.34 Million	130,400 Added 11.62%	1,252,152 $10.1 Million
Q4 2022 Feb 13, 2023	SELL	$14.33 - $18.37 $908,894 - $1.17 Million	-63,426 Reduced 5.35%	1,121,752 $17.7 Million
Q3 2022 Nov 14, 2022	SELL	$13.07 - $18.22 $1.89 Million - $2.63 Million	-144,500 Reduced 10.87%	1,185,178 $18.7 Million
Q2 2022 Aug 12, 2022	SELL	$10.16 - $17.08 $1.3 Million - $2.18 Million	-127,900 Reduced 8.77%	1,329,678 $18.6 Million
Q1 2022 May 13, 2022	SELL	$9.74 - $17.92 $2.14 Million - $3.93 Million	-219,300 Reduced 13.08%	1,457,578 $25.1 Million
Q4 2021 Feb 11, 2022	SELL	$12.27 - $18.49 $4.22 Million - $6.36 Million	-344,000 Reduced 17.02%	1,676,878 $24.4 Million
Q3 2021 Nov 12, 2021	SELL	$13.38 - $18.8 $5.5 Million - $7.73 Million	-411,000 Reduced 16.9%	2,020,878 $36.4 Million
Q2 2021 Aug 13, 2021	SELL	$17.08 - $29.6 $9.47 Million - $16.4 Million	-554,600 Reduced 18.57%	2,431,878 $42.7 Million
Q1 2021 May 13, 2021	SELL	$5.86 - $27.73 $1.65 Million - $7.81 Million	-281,700 Reduced 8.62%	2,986,478 $75.3 Million
Q4 2020 Feb 10, 2021	SELL	$2.65 - $7.61 $437,811 - $1.26 Million	-165,212 Reduced 4.81%	3,268,178 $21.1 Million
Q3 2020 Nov 13, 2020	BUY	$1.5 - $2.71 $230,325 - $416,120	153,550 Added 4.68%	3,433,390 $8.82 Million
Q2 2020 Aug 13, 2020	BUY	$1.04 - $1.73 $108,372 - $180,272	104,204 Added 3.28%	3,279,840 $5.31 Million
Q1 2020 May 14, 2020	BUY	$0.75 - $2.18 $295,004 - $857,479	393,339 Added 14.14%	3,175,636 $3.3 Million
Q4 2019 Feb 13, 2020	BUY	$1.02 - $1.97 $829,852 - $1.6 Million	813,581 Added 41.33%	2,782,297 $5.26 Million
Q3 2019 Nov 13, 2019	BUY	$0.79 - $2.47 $1 Million - $3.13 Million	1,269,136 Added 181.41%	1,968,716 $2.13 Million
Q2 2019 Aug 12, 2019	BUY	$2.13 - $7.06 $579,786 - $1.92 Million	272,200 Added 63.69%	699,580 $1.53 Million
Q1 2019 May 14, 2019	BUY	$5.63 - $7.84 $1.87 Million - $2.6 Million	331,700 Added 346.68%	427,380 $2.56 Million
Q4 2018 Feb 13, 2019	BUY	$6.3 - $15.4 $602,784 - $1.47 Million	95,680 New	95,680 $707,000

Others Institutions Holding ACRS

# of Institutions

Shares Held

52.4M

Call Options Held

32.4K

Put Options Held

3.3K

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $139M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account